~~<i id='C7B78896BA'><strike id='C7B78896BA'><tt id='C7B78896BA'><pre id='C7B78896BA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：explore 2025-09-06 06:17:10 - browse：553

Adam's take main illustration — Molly Ferguson/STAT

I was wrong about Geron.

For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.

On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Change Healthcare can notify patients about the breach, HHS says

entertainment

knowledge

hotspot

focus

Scanningelectronmicrographofhumanrespiratorysyncytialvirus.NIAIDApanelofexperts thatadvisestheCenter

WSS

Why more medical students aren't specializing in primary care

Feds fine Medicare Advantage plans for overcharging members

AstraZeneca challenges Medicare drug negotiation program

What AAP's gender

Appeals court upholds limits to abortion pill

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

explore

leisure time

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

AstraZeneca bets AAV gene therapy will still deliver the goods

George Santos makes 1st court appearance after pleading not guilty to 13 counts

In science, is the line between industry and academia shifting?

Cancer drug shortages should be causing more outrage

What do new weight loss drugs mean for bariatric surgery?

Sports medicine is finally prioritizing gender equality

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

The high cost of giving birth even with insurance

Letters to First Opinion on caregivers, digital health, and more

entertainment

Why more medical students aren't specializing in primary care

Drug firms test therapies to halt Alzheimer’s before symptoms arise

NYU Langone launches private ChatGPT for its health care data

How to make AI work for medicine

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

What do new weight loss drugs mean for bariatric surgery?

knowledge

knowledge

hotspot

focus